FGEN Overview

Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Wall Street analysts forecast FGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGEN is43.00 USD with a low forecast of 43.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

FibroGen Inc revenue for the last quarter amounts to 1.08M USD, increased 774.80

FibroGen Inc. EPS for the last quarter amounts to 49.61 USD, decreased -1267.29

FibroGen Inc (FGEN) has 225 emplpoyees as of March 12 2026.

Today FGEN has the market capitalization of 102.46M USD.